AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01258075
Drug: Low-dose colesevelam
RxNorm normalized name: ethinyl estradiol
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.625 grams colesevelam hydrochloride in oral suspension
Trial: NCT01200732
Drug: Tadalafil, placebo
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg tablets, 2 tablets Once daily(i.e 40mg once daily) 20mg placebo 2 tablets once daily
Trial: NCT01741506
Drug: Dalteparin (Fragmin®)
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02856425
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details
Trial: NCT00801437
Drug: Xalacom
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Xalacom 1 drop into the affected eye daily
Trial: NCT01181115
Drug: Avonex
RxNorm normalized name: Avonex
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon treatment for MS
Trial: NCT01288339
Drug: Panitumumab + FOLFOX (DP)
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab and FOLFOX will be administered to patients with DP once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
Trial: NCT01288339
Drug: Panitumumab + FOLFOX (no-DP)
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab and FOLFOX will be administered to patients with no-DP (MMP7+/p-IGF-IR-, MMP7-/p-IGF-IR+ or MMP7-/p-IGF-IR) once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
Trial: NCT00001783
Drug: 0-15 Water
RxNorm normalized name: water, O-15
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02737228
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m\^2 intravenously every week three times per cycle (4 weeks)
Trial: NCT02737228
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg per oral daily per cycle (4 weeks)
Trial: NCT04500496
Drug: INH
RxNorm normalized name: INH
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 tablet of INH inserted by the patient 12 hours before the scheduled office hysteroscopy
Trial: NCT02223819
Drug: Crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: An anti-cancer drug acting as an anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) inhibitor, used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in a gene called ALK.~Crizotinib will be provided as capsules containing 200 or 250 mg of study medication for oral administration.
Trial: NCT01511718
Drug: Ondansetron Hydrochloride
RxNorm normalized name: Ondansetron Hydrochloride
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron Hydrochloride Tablets 8 mg
Trial: NCT01511718
Drug: Ondansetron Hydrochloride
RxNorm normalized name: Ondansetron Hydrochloride
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zofran Tablets 8 mg
Trial: NCT02337517
Drug: Vismodegib
RxNorm normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT03258008
Drug: Utomilumab
RxNorm normalized name: Utomilumab
DrugBank: Utomilumab (DB15113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Utomilumab given by vein on Cycle 1 Day 1. Cycle 1-2 100 mg, Cycle 3-12 50 mg until progressive disease, toxicity, or 1 yr.
Trial: NCT00642902
Drug: Atacicept
RxNorm normalized name: Atacicept
DrugBank: Atacicept (DB06399)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atacicept will be administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 32 weeks.
Trial: NCT02651519
Drug: 0.25% ropivacaine hydrochloride
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: stellate-ganglion block with 0.25% ropivacaine hydrochloride
Trial: NCT00642902
Drug: Atacicept
RxNorm normalized name: Atacicept
DrugBank: Atacicept (DB06399)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atacicept will be administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 32 weeks.
Trial: NCT00642902
Drug: Atacicept
RxNorm normalized name: Atacicept
DrugBank: Atacicept (DB06399)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atacicept will be administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
Trial: NCT00642902
Drug: Placebo matched to atacicept
DrugBank: Atacicept (DB06399)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
Trial: NCT02651519
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: stellate-ganglion block with saline
Trial: NCT01373216
Drug: Exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative continuous i.v. administration of exenatide lasting for 72 hours - 40 ng/min for initial 30 min, 20 ng/min for remaining 71.5 hours
Trial: NCT00339196
Drug: 5 azacytidine - VALPROIC acid- Retinoic acid
RxNorm normalized name: Retinoic acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 azacytidine - VALPROIC acid- Retinoic acid
Trial: NCT02322502
Drug: Desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: inhalation with laryngeal mask to maintain anaesthesia
Trial: NCT02322502
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: inhalation with laryngeal mask to maintain anaesthesia
Trial: NCT02322502
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous injection to maintain anaesthesia
Trial: NCT00835627
Drug: sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: flexible dose sertraline
Trial: NCT01591551
Drug: Natalizumab (Tysabri)
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300 mg IV every 4 weeks
Trial: NCT02768610
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02098187
Drug: Below target dose MP-3180
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MP-3180 0.5 µmol/kg (0.186 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
Trial: NCT02098187
Drug: At target dose MP-3180
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MP-3180 1 µmol/kg (0.186 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
Trial: NCT02180997
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily
Trial: NCT02098187
Drug: 2 times above target dose MP-3180
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MP-3180 2 µmol/kg (0.744 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
Trial: NCT02098187
Drug: 4 times above target dose MP-3180
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MP-3180 4 µmol/kg (1.488 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
Trial: NCT02401464
Drug: TAK-536 Tablet
RxNorm normalized name: TAK-243
DrugBank: TAK-593 (DB13093)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-536 10 mg tablet
Trial: NCT02180997
Drug: Solifenacin
RxNorm normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin and solifenacin: Solifenacin 10 mg, once daily
Trial: NCT01493505
Drug: AMG 386
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 386 15mg/kg IV QW (until progression or unacceptable toxicity develops)
Trial: NCT01493505
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m2 3 hour IV Q3W (6 cycles)
Trial: NCT01493505
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC 5 or 6 IV Q3W (6 cycles)
Trial: NCT03462966
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin will be administered to patients diagnosed with IBS-D or IBS-M to evaluate whether the medication is effective in decreasing rectal hypersensitivity. The secondary objective of the study is to assess the role of SIBO in rectal sensitivity.
Trial: NCT00915135
Drug: Ramelteon and Placebo (25 possible combinations total)
RxNorm normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Randomized sequence over two consecutive nights for a total of five treatment periods to include the following:~Ramelteon 4 mg, tablets, orally over two nights~Ramelteon 8 mg, tablets, orally over two nights~Ramelteon 16 mg, tablets, orally over two nights~Ramelteon 32 mg, tablets, orally over two nights~Ramelteon placebo-matching tablets, orally over two nights
Trial: NCT01119768
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg Esomeprazole once daily, 8 weeks and 24 weeks on-demand treatment
Trial: NCT01119768
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg Esomeprazole once daily, 2 weeks and 24 weeks follow up
Trial: NCT03356730
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only patients with vitamin D deficiency / deficiency will be included in the study. Randomly, they will be divided into two groups. This group will receive vitamin D supplementation.~Vitamin D3 - cholecalciferol, oral suspension in drops, will be prescribed as follows:~• 5,000 IU / day - 10 drops per day for two months.
Trial: NCT03850080
Drug: Autologous Conditioned Serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fifteen patients with clinical and radiological signs of OA of the knee were recruited for this study. 50mL of whole blood were taken using a special syringe containing CrSO4-coated grade glass beads in order to promote IL-1ra synthesis and aggregation.The incubation period lasted 7 hours after which, the blood-filled syringes were centrifuged and the serum supernatant was filtered and aliquoted into four 3mL portions. The aliquots were stored at -20oC until their use was necessary.~Patients received 1 intra-articular injection for 4 consecutive weeks at the site of OA.
Trial: NCT00886028
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 80 mg/m2 every 4 weeks for 6 cycles.~Thirty patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias were included to receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles.
Trial: NCT03270514
Drug: Bupivacaine Hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% 2 mg/kg not to exceed 150 mg - made up to made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)
Trial: NCT00895882
Drug: vaniprevir (MK7009)
RxNorm normalized name: Vaniprevir
DrugBank: Vaniprevir (DB11929)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: vaniprevir 300 mg soft gel capsules twice daily.
Trial: NCT00895882
Drug: Comparator: vaniprevir (MK7009)
DrugBank: Vaniprevir (DB11929)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: vaniprevir 600 mg soft gel capsules twice daily.
Trial: NCT00895882
Drug: Comparator: Pegylated Interferon (peg-IFN) alfa-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peg-IFN 180 mcg/0.5 mL subcutaneous injection once weekly
Trial: NCT00895882
Drug: Comparator: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin, at a total daily dose of 1000 mg or 1200 mg based on patient weight, will be administered twice daily.
Trial: NCT02180997
Drug: Tamsulosin and solifenacin
RxNorm normalized name: tamsulosin and solifenacin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily, Solifenacin 10 mg, once daily
Trial: NCT00895882
Drug: Comparator: Placebo to vaniprevir
DrugBank: Vaniprevir (DB11929)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Placebo to vaniprevir soft gel capsules twice daily.
Trial: NCT02382796
Drug: Dacomitinib
RxNorm normalized name: DACOMITINIB
DrugBank: Dacomitinib (DB11963)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting at the current dose level in the prior study. Dose reductions and re-escalations are allowed based on tolerability. Patients may continue to be treated with dacomitinib on this protocol as long as there is evidence of clinical benefit in the judgment of the investigator.
Trial: NCT04411602
Drug: SARS-CoV-2 plasma
RxNorm normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To determine feasibility of convalescent plasma for treating patients in the ICU with COVID-19.
Trial: NCT03852849
Drug: The dosage of 400mg EFV
RxNorm normalized name: Extract of the Sterile Caules of Equisetum Arvense
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage of 400mg EFV will be used in the antiviral therapy.
Trial: NCT02801669
Drug: Du-176b
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DU-176b orally administered at a dose of 15 mg once daily.
Trial: NCT00993239
Drug: Birinapant (TL32711)
RxNorm normalized name: Birinapant
DrugBank: Birinapant (DB11782)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 minute intravenous (IV) infusion administered once weekly for three consecutive weeks followed by a one week off (Cycle) repeated every 4 weeks as tolerated
Trial: NCT02465502
Drug: Regorafenib (Stivarga, BAY73-4506)
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 160 mg orally once a day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).
Trial: NCT02295566
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Not required
Trial: NCT00596596
Drug: prucalopride
RxNorm normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 0,5 mg once daily
Trial: NCT00596596
Drug: prucalopride
RxNorm normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 mg once daily
Trial: NCT00596596
Drug: 2 mg prucalopride
RxNorm normalized name: prucalopride 2 MG
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2 mg once daily
Trial: NCT00596596
Drug: 4 mg prucalopride
RxNorm normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg once daily
Trial: NCT03356899
Drug: Low dose bupivacaine 0.5% (8mg)
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 mg hyperbaric bupivacaine with added 25 µg fentanyl to form a total volume of 2.1 ml
Trial: NCT03356899
Drug: High dose bupivacaine 0.5% (10mg)
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg hyperbaric bupivacaine with added 25 µg fentanyl to form a total volume of 2.5
Trial: NCT02156375
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive a single 6 milligram per kilogram (mg/kg) intravenous infusion of 90 milligram per milliliter (mg/mL) liquid in vial (LIV) formulation, diluted in saline, on Day 1.
Trial: NCT02156375
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive a single 6 mg/kg intravenous infusion of 5 mg/mL LIV formulation, diluted in saline, on Day 1.
Trial: NCT01447875
Drug: propofol or mexmedetomidine
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00976209
Drug: Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg
RxNorm normalized name: guaifenesin / phenylephrine hydrochloride Extended Release Oral Tablet
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylephrine HCl ER tablets 30 mg taken every 12 hours, twice daily, for 3 days.
Trial: NCT00976209
Drug: Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mg
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylephrine HCl IR tablets 10 mg taken every four hours (no more than 6 times daily) for 3 days.
Trial: NCT04007107
Drug: Semaglutide (administered by DV3396 pen)
RxNorm normalized name: semaglutide Pen Injector
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
Trial: NCT04007107
Drug: Semaglutide (administered by PDS290 pen)
RxNorm normalized name: semaglutide Pen Injector
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
Trial: NCT00551161
Drug: memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24-week observational lead-in period, wherein patients already on a stable dose of donepezil, rivastigmine, or galantamine continue on that dose, followed by a 24-week open-label memantine period, wherein patients receive open-label memantine treatment titrated to a dose of 10 mg orally b.i.d., in addition to their ongoing stable cholinesterase inhibitor treatment
Trial: NCT00237250
Drug: vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT01866267
Drug: Maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HIV positive patients infected with CCR5 tropic virus that have achieved an undetectable viral load on a non-Selzentry®-containing regimen \[Protease Inhibitor (PI)/Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)/Integrase Inhibitor plus 2 Nucleoside Reverse Transcriptase Inhibitor (NRTI)\] are switched to once-daily Selzentry® (600mg qd) plus the same 2 NRTIs previously administered.
Trial: NCT01363128
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01363128
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or PO
Trial: NCT01363128
Drug: Vincristine Sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04119947
Drug: SY-009
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study will be initiated in healthy subjects at a 0.5mg dose that is the maximum recommended starting dose(MRSD) . Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 2,5, 10, 20, 40mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
Trial: NCT01169402
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg/kg intravenously once weekly while on ECMO
Trial: NCT04690309
Drug: Treatment with human insulin preparations or treatment with insulin analogues
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The doses of human insulin preparations and insulin analogues will be matched individually to achieve target values of blood glucose - fasting \< 100 mg/dl (5.5 mmol/L) and postprandial \< 140 mg/dl (7.8mmol/L)